USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment

ChangeBridge: Patent Apps - Peptides (C07K)

Published September 18th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.

View original document View source feed page

What changed

This document is a publication of a US patent application (US20260083777A1) filed on September 18, 2023, by Sonoma Biotherapeutics, Inc. The application details chimeric antigen receptors (CARs) that recognize citrullinated polypeptides, specifically mentioning citrullinated vimentin, which are found in skin lesions of patients with hidradenitis suppurativa. The invention also covers T cells, particularly Treg cells, engineered to express these CARs, and their administration for treating the condition.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signifies potential future developments in therapeutic treatments for hidradenitis suppurativa. Companies involved in pharmaceutical research, biotechnology, and the development of treatments for autoimmune or dermatological conditions should be aware of this filing as it may impact intellectual property landscapes and future market competition.

Source document (simplified)

← USPTO Patent Applications

CITRULLINATED ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR TARGETING REGULATORY T CELLS TO TREAT HIDRADENITIS SUPPURATIVA

Application US20260083777A1 Kind: A1 Mar 26, 2026

Assignee

Sonoma Biotherapeutics, Inc.

Inventors

Leonard DRAGONE, Joshua BEILKE

Abstract

Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subjects with hidradenitis suppurativa. Further disclosed are T cells, and in particular, Treg cells that express these CARs. Administration of these CAR-T cells is useful in the treatment of hidradenitis suppurativa.

CPC Classifications

A61K 35/17 A61K 40/11 A61K 40/31 A61K 40/416 C07K 14/535 C07K 14/7051 C07K 14/70517 C07K 14/70521 C07K 16/18 C12N 5/0637 A61K 2239/13 A61K 2239/17 A61K 2239/21 C07K 2317/53 C07K 2317/565 C07K 2317/622 C07K 2319/02 C07K 2319/03 C12N 2510/00